More

• Datawatch buying Panopticon in $31.4M stock deal Monday, 17 Jun 2013 | 12:56 PM ET

  CHELMSFORD, Mass.-- Datawatch is buying real-time visual data software company Panopticon Software AB in an all-stock deal valued at about $31.4 million. Datawatch, which is based in Chelmsford, Mass., provides information optimization products that help businesses analyze and manage data.

• PDL BioPharma wants arbitration in royalty dispute Tuesday, 11 Jun 2013 | 11:56 AM ET

  INCLINE VILLAGE, Nev.-- PDL BioPharma Inc. said Tuesday it wants take Roche's Genentech business to arbitration over a royalty payment dispute. The company filed a notice with the American Arbitration Association in New Jersey.

• Questcor will pay at least $135M for Novartis drug Tuesday, 11 Jun 2013 | 10:46 AM ET

  NEW YORK-- Questcor Pharmaceuticals Inc. said Tuesday it will pay at least $135 million to buy an autoimmune and inflammatory disease drug made by Novartis AG, sending its shares surging in morning trading. Shares of Questcor jumped $8.30, or 22.6 percent, to $45.01 in morning trading.

• Sanofi MS drug nears green light after pass-the-parcel marathon Monday, 10 Jun 2013 | 7:45 AM ET

  LONDON, June 10- One of the world's longest running drug development sagas may draw to a close this month as French firm Sanofi hopes for a European green light for its new multiple sclerosis medicine Lemtrada.

• UPDATE 1-AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 bln Monday, 10 Jun 2013 | 2:51 AM ET

  *Purchase takes AstraZeneca into emerging LABA/LAMA market. LONDON, June 10- AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.

• Momenta Pharma rises following upgrade from UBS Thursday, 6 Jun 2013 | 4:43 PM ET

  NEW YORK-- Shares of Momenta Pharmaceuticals Inc. jumped Thursday after a UBS analyst upgraded the shares, saying she thinks it's more likely the company will be able to start selling a generic version of the multiple sclerosis drug Copaxone in the next few years.

• EXCLUSIVE-EU to fine Lundbeck, others for blocking generic drugs Monday, 3 Jun 2013 | 11:17 AM ET

  BRUSSELS, June 3- A European regulator will fine Denmark's Lundbeck and eight other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against "pay-for-delay" deals.

• UPDATE 3-Canada drugmaker Valeant to buy Bausch & Lomb for $8.7 billion Monday, 27 May 2013 | 1:16 PM ET

  *Valeant shares hit all-time high in Toronto. TORONTO/ WINNIPEG, Manitoba, May 27- Valeant Pharmaceuticals International said on Monday it agreed to buy Bausch& Lomb Holdings Inc from Warburg Pincus LLC for $8.7 billion, a cash deal set to vault the Canadian company into the upper ranks of the global pharmaceutical sector.

• FEATURE-Pfizer takes its shot at a vaccine for evasive superbug Thursday, 23 May 2013 | 12:59 AM ET

  CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.

• Immune system cancer drugs tipped to be a $35 bln market Wednesday, 22 May 2013 | 5:33 AM ET

  *Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.

• DEALTALK-Novartis' Vasella exit opens door to Roche stake sale Thursday, 16 May 2013 | 12:04 PM ET

  *Novartis' one-third stake in Roche built up under Vasella. ZURICH, May 16- A changing of the guard at Switzerland's two biggest drugmakers is fuelling talk that Novartis may finally sell its multi-billion-dollar stake in cross-town rival Roche, potentially unlocking value for both sets of shareholders.

• Early Movers: WMT, KSS, CSCO & More Thursday, 16 May 2013 | 7:33 AM ET

  

  Some of the names on the move ahead of the open.

• SEC says new settlements end 'Golden Goose' insider trading case Wednesday, 15 May 2013 | 7:09 PM ET

  *Jamil Bouchareb, Daniel Corbin settle civil cases. Jamil Bouchareb agreed to pay about $1.05 million and fellow trader Daniel Corbin agreed to pay about $191,000 in disgorged profit plus interest to settle the SEC's civil cases, after having previously pleaded guilty to related criminal charges.

• Swiss stocks lift European shares to fresh heights Wednesday, 15 May 2013 | 12:48 PM ET

  *FTSEurofirst 300 closes up 0.7 pct at 1,245.66 points. LONDON, May 15- European shares scaled new five-year highs on Wednesday, led by gains for several major Swiss stocks after a fresh fall on the Swiss franc that should continue to buoy the country's exporters.

• Swiss stocks push European shares to fresh peaks Wednesday, 15 May 2013 | 11:35 AM ET

  LONDON, May 15- European shares scaled fresh five-year highs on Wednesday, led by gains for several major Swiss stocks after a currency shift that should continue to buoy the country's exporters. The pan-European FTSEurofirst 300 index provisionally closed up 0.7 percent at 1,245.41 points, its highest level since mid-2008.

• Europe Shares Close Higher as Risk-On Rally Resumes Wednesday, 15 May 2013 | 11:07 AM ET

  European shares were higher in early afternoon trade on Wednesday despite preliminary growth data from the euro zone missing estimates.

• U.S. urged to take tougher line on Indian trade practices Tuesday, 14 May 2013 | 4:37 PM ET

  *India is largest beneficiary in U.S. trade benefit program. WASHINGTON, May 14- A U.S. think tank on Tuesday recommended Congress suspend trade benefits for India, in the latest sign of U.S. frustration over Indian policies that block American exports and "free ride" on costly U.S. research to develop new medicines and other forms of valuable intellectual property.

• A taste for defensives sours prospects for European stocks Tuesday, 14 May 2013 | 7:32 AM ET

  *Defensive stocks unusually leading Europe stock rally. LONDON, May 14- Defensive stocks such as healthcare companies, which often bring up the rear when markets rise, have led the gainers in 2013 as European bourses hit their highest in years, suggesting investors don't think the good times will roll for long.

• RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices Friday, 10 May 2013 | 2:26 PM ET

  Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe's government-run health plans clamp down on spending and sales growth in emerging markets stutters.

• Telecoms stocks lift Europe equities to new peaks Friday, 10 May 2013 | 1:01 PM ET

  *BT and Novartis boost telecom and health stocks. LONDON, May 10- European shares scaled fresh five-year highs on Friday, led by telecoms and healthcare stocks, and traders said key indexes had scope for further gains, with any near-term pullback likely to be short-lived.